Testosterone Stimulating Erythropoiesis
Placeholder: testosterone raises EPO and marrow RBC production.
- +20–40%: EPO stimulation (Placeholder short note)
- Weeks: Marrow response (Placeholder short note)
- Increased: Iron utilization (Placeholder short note)
- ~45%: Baseline hct (Placeholder short note)
Mechanism of stimulation
Placeholder: testosterone increases erythropoietin and suppresses hepcidin.
Rising Hematocrit and Blood Viscosity
Placeholder: hematocrit and viscosity climb progressively on therapy.
- 3–5 pts: Typical rise (Placeholder short note)
- 3–12 mo: Onset (Placeholder short note)
- Nonlinear: Viscosity effect (Placeholder short note)
- ~12 mo: Plateau (Placeholder short note)
Viscosity dynamics
Placeholder: viscosity rises steeply once hematocrit exceeds normal range.
Thrombotic Risk Threshold (Hct > 54%)
Placeholder: hematocrit above 54% sharply raises clot risk.
- 54%: Risk threshold (Placeholder short note)
- 50–54%: Action level (Placeholder short note)
- Elevated: Stroke/VTE risk (Placeholder short note)
- Endocrine Society: Guideline basis (Placeholder short note)
Why 54% matters
Placeholder: this threshold marks a steep rise in thrombosis risk.
Monitoring Schedule During Therapy
Placeholder: scheduled hematocrit checks catch rises early.
- Pre-therapy: Baseline check (Placeholder short note)
- 3, 6, 12 mo: Follow-up (Placeholder short note)
- Annual: Ongoing (Placeholder short note)
- CBC/Hct: Test used (Placeholder short note)
Recommended cadence
Placeholder: check hematocrit at 3, 6, and 12 months, then yearly.
Dose Reduction or Phlebotomy Response
Placeholder: lowering dose or phlebotomy brings hematocrit back down.
- ~500 mL: Phlebotomy volume (Placeholder short note)
- ~25–50%: Dose cut (Placeholder short note)
- 4–6 wk: Recheck interval (Placeholder short note)
- <50%: Target hct (Placeholder short note)
Corrective options
Placeholder: phlebotomy or dose reduction restores safe hematocrit.
Placeholder: combined monitoring and response keeps therapy safe.